CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Eli Lilly and Company

LLY
$769.79B
Mega Cap
NYSEPharmaceutical PreparationsPharmaceutical🇺🇸North AmericaINDIANAPOLIS47.0K employees

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Website

Drugs in Pipeline

350

Phase 3 Programs

193

Upcoming Catalysts

37

Next Catalyst

Feb 15, 2026

7d
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

37 upcoming, 1 past

Phase 2Next

LY3871801 Phase 2 Results Expected

February 2026~LY3871801

Primary completion for LY3871801 trial (NCT05848258) in Rheumatoid Arthritis

Source
Phase 2

LY3541860 Phase 2 Results Expected

February 2026~LY354186040

Primary completion for LY3541860 trial (NCT06859294) in Rheumatoid Arthritis

Source
⭐Phase 3

Insulin Glargine Phase 3 Results Expected

March 2026~Insulin Glargine2,749

Primary completion for Insulin Glargine trial (NCT05803421) in Type 2 Diabetes

Source
⭐Phase 3

Orforglipron Phase 3 Results Expected

March 2026~Orforglipron2,749

Primary completion for Orforglipron trial (NCT05803421) in Type 2 Diabetes

Source
⭐Phase 3

Retatrutide Phase 3 Results Expected

April 2026~Retatrutide2,300

Primary completion for Retatrutide trial (NCT05882045) in Obesity

Source
Phase 2

Bimagrumab Phase 2 Results Expected

April 2026~Bimagrumab240

Primary completion for Bimagrumab trial (NCT06643728) in Obesity

Source
⭐Phase 3

Baricitinib Phase 3 Results Expected

April 2026~Baricitinib58

Primary completion for Baricitinib trial (NCT04088396) in Systemic Juvenile Idiopathic Arthritis

Source
Phase 2

LY3549492 Phase 2 Results Expected

April 2026~LY3549492275

Primary completion for LY3549492 trial (NCT06683508) in Obesity

Source
⭐Phase 3

Mirikizumab IV Phase 3 Results Expected

May 2026~Mirikizumab IV60

Primary completion for Mirikizumab IV trial (NCT05784246) in Ulcerative Colitis

Source
⭐Phase 3

Retatrutide Phase 3 Results Expected

May 2026~Retatrutide1,000

Primary completion for Retatrutide trial (NCT05929079) in Type 2 Diabetes

Source
Phase 2

Mevidalen Phase 2 Results Expected

May 2026~Mevidalen300

Primary completion for Mevidalen trial (NCT06538116) in Alzheimer Disease

Source
⭐Phase 3

Tirzepatide Phase 3 Results Expected

May 2026~Tirzepatide150

Primary completion for Tirzepatide trial (NCT06047548) in Overweight

Source
Phase 2

LY3848575 Phase 2 Results Expected

June 2026~LY3848575450

Primary completion for LY3848575 trial (NCT06568042) in Neuropathic Pain

Source
Phase 2

LY3841136 Phase 2 Results Expected

June 2026~LY38411361,217

Primary completion for LY3841136 trial (NCT06603571) in Obesity

Source
Phase 2

Tirzepatide Phase 2 Results Expected

June 2026~Tirzepatide1,217

Primary completion for Tirzepatide trial (NCT06143956) in Obesity

Source
Phase 2

LY3305677 Phase 2 Results Expected

June 2026~LY33056771,217

Primary completion for LY3305677 trial (NCT06143956) in Obesity

Source
⭐Phase 3

Lebrikizumab Phase 3 Results Expected

July 2026~Lebrikizumab206

Primary completion for Lebrikizumab trial (NCT06921759) in Atopic Hand and Foot Dermatitis

Source
Phase 2

Mazdutide Phase 2 Results Expected

August 2026~Mazdutide300

Primary completion for Mazdutide trial (NCT06817356) in Alcohol Use Disorder

Source
⭐Phase 3

Retatrutide Phase 3 Results Expected

August 2026~Retatrutide

Primary completion for Retatrutide trial (NCT06260722) in Diabetes Mellitus, Type 2

Source
⭐Phase 3

Semaglutide Phase 3 Results Expected

August 2026~Semaglutide

Primary completion for Semaglutide trial (NCT06260722) in Diabetes Mellitus, Type 2

Source
⭐Phase 3

LY3650150 Phase 3 Results Expected

September 2026~LY3650150450

Primary completion for LY3650150 trial (NCT06339008) in Perennial Allergic Rhinitis (PAR)

Source
Phase 2

Tirzepatide Phase 2 Results Expected

September 2026~Tirzepatide140

Primary completion for Tirzepatide trial (NCT05536804) in Overweight

Source
⭐Phase 3

LY3537982 Phase 3 Results Expected

October 2026~LY35379821,016

Primary completion for LY3537982 trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source
⭐Phase 3

Retatrutide Phase 3 Results Expected

October 2026~Retatrutide320

Primary completion for Retatrutide trial (NCT06297603) in Type 2 Diabetes

Source
⭐Phase 3

Cisplatin Phase 3 Results Expected

October 2026~cisplatin1,016

Primary completion for Cisplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source
⭐Phase 3

Carboplatin Phase 3 Results Expected

October 2026~carboplatin1,016

Primary completion for Carboplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source
⭐Phase 3

Pembrolizumab Phase 3 Results Expected

October 2026~Pembrolizumab1,016

Primary completion for Pembrolizumab trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source
⭐Phase 3

Pemetrexed Phase 3 Results Expected

October 2026~pemetrexed1,016

Primary completion for Pemetrexed trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source
⭐Phase 3

Orforglipron Phase 3 Results Expected

November 2026~Orforglipron600

Primary completion for Orforglipron trial (NCT06649045) in OSA

Source
⭐Phase 3

Lasmiditan Phase 3 Results Expected

November 2026~Lasmiditan

Primary completion for Lasmiditan trial (NCT04396236) in Migraine

Source
Phase 2

LY3938577 Phase 2 Results Expected

November 2026~LY3938577100

Primary completion for LY3938577 trial (NCT07215312) in Diabetes Mellitus, Type 2

Source
Phase 2

MORF-057 Phase 2 Results Expected

November 2026~MORF-05739

Primary completion for MORF-057 trial (NCT06226883) in Inflammatory Bowel Diseases

Source
⭐Phase 3

Tirzepatide Phase 3 Results Expected

December 2026~Tirzepatide800

Primary completion for Tirzepatide trial (NCT06662383) in Obesity

Source
Phase 2

Pirtobrutinib Phase 2 Results Expected

December 2026~Pirtobrutinib58

Primary completion for Pirtobrutinib trial (NCT06721013) in Immune Thrombocytopenia (ITP)

Source
Phase 2

LY3457263 Phase 2 Results Expected

December 2026~LY3457263240

Primary completion for LY3457263 trial (NCT06897475) in Type 2 Diabetes

Source
⭐Phase 3

Retatrutide Phase 3 Results Expected

December 2026~Retatrutide800

Primary completion for Retatrutide trial (NCT06662383) in Obesity

Source
⭐Phase 3

Orforglipron Phase 3 Results Expected

January 2027~Orforglipron1,200

Primary completion for Orforglipron trial (NCT06972472) in Obesity

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Atomoxetine

Phase 3

Attention Deficit Hyperactivity Disorder

teriparatide

Phase 3

Osteoporosis, Postmenopausal

Necitumumab

Phase 3

Solid Tumors

Doxorubicin

Phase 3

Breast Cancer

enzastaurin

Phase 3

Non-Small Cell Lung Cancer

Paclitaxel

Phase 3

Non Small Cell Lung Cancer

Insulin Lispro

Phase 3

Type 2 Diabetes Mellitus

Somatropin (rDNA origin) for injection

Phase 3

Failure to Thrive

Rapid Acting Intramuscular Olanzapine

Phase 3

Schizophrenia

LY3650150

Phase 3

Perennial Allergic Rhinitis (PAR)

somatropin, rDNA origin, for injection

Phase 3

Growth Disorder

LY2189265

Phase 3

Diabetes Mellitus, Type 2

Sulfonylureas (SU)

Phase 3

Type 2 Diabetes Mellitus

50 mg etanercept

Phase 3

Psoriasis

Abemaciclib

Phase 3

Breast Cancer

LY2127399

Phase 3

Arthritis, Rheumatoid

Capecitabine

Phase 3

Metastatic Gastric Adenocarcinoma

Testosterone Solution

Phase 3

Hypogonadism

Pregabalin

Phase 3

Diabetic Neuropathy, Painful

Tadalafil

Phase 3

Benign Prostatic Hyperplasia

Letrozole

Phase 3

Breast Cancer

Fulvestrant

Phase 3

Breast Neoplasms

Ixekizumab 80 mg Q4W

Phase 3

Psoriatic Arthritis

Methylphenidate

Phase 3

Attention Deficit Hyperactivity Disorder

Ultra-Rapid Lispro

Phase 3

Type 1 Diabetes Mellitus

Paclitaxel (Taxane)

Phase 3

Non-Small-Cell Lung Carcinoma

Arzoxifene

Phase 3

Osteoporosis, Postmenopausal

Mirikizumab

Phase 3

Ulcerative Colitis

Glargine

Phase 3

Diabetes Mellitus, Type 1

lithium

Phase 3

Manic or Mixed Episode Associated With Bipolar I Disorder

Human Insulin Inhalation Powder

Phase 3

Diabetes Mellitus, Type 2

Liraglutide

Phase 3

Type 2 Diabetes Mellitus

dexamethasone

Phase 3

Non Small Cell Lung Cancer

Donanemab

Phase 3

Alzheimer Disease

Etesevimab

Phase 3

COVID-19

Human regular U-500 insulin (CSII)

Phase 3

Type 2 Diabetes Mellitus

carboplatin

Phase 3

Breast Cancer

Imlunestrant

Phase 3

Breast Neoplasms

Insulin Lispro Protamine Suspension

Phase 3

Diabetes Mellitus, Type 2

Somatropin

Phase 3

Growth Hormone Deficiency

Nasal Glucagon

Phase 3

Hypoglycemia

Atomoxetine Hydrochloride

Phase 3

Attention Deficit Hyperactivity Disorder

Ramucirumab

Phase 3

Gastric Adenocarcinoma

LY3819253

Phase 3

COVID-19

LY900014

Phase 3

Type 1 Diabetes Mellitus

Rapid-Acting Intramuscular Olanzapine

Phase 3

Schizophrenia

Olanzapine and Fluoxetine combination (OFC)

Phase 3

Treatment Resistant Depression

Detemir

Phase 3

Diabetes Mellitus Type 2

Glimepiride

Phase 3

Diabetes Mellitus, Type 2

docetaxel

Phase 3

Non-Small Cell Lung Cancer

Gemcitabine

Phase 3

Non-Small Cell Lung Cancer

sildenafil

Phase 3

Impotence

Lasmiditan

Phase 3

Migraine

Insulin Glargine

Phase 3

Diabetes Mellitus, Type 2

Pegilodecakin

Phase 3

Pancreatic Cancer

Duloxetine (DLX)

Phase 3

Osteoarthritis Knee Pain

Duloxetine Hydrochloride (HCI)

Phase 3

Multiple Sclerosis

tadalafil once a day [T(OaD)]

Phase 3

Erectile Dysfunction

Paroxetine

Phase 3

Major Depressive Disorder

Olanzapine Hydrochloride

Phase 3

Bipolar Disorder

Galunisertib

Phase 3

Glioblastoma

prednisone

Phase 3

Prostate Cancer

Humalog Mix 50

Phase 3

Diabetes Mellitus, Type 1

Oral antihyperglycemics

Phase 3

Diabetes Mellitus

Ixekizumab Auto-Injector

Phase 3

Plaque Psoriasis

Aducanumab

Phase 3

Mild Cognitive Impairment (MCI)

Etanercept

Phase 3

Plaque Psoriasis

80 mg ixekizumab

Phase 3

Psoriasis

LY2216684 (edivoxetine)

Phase 3

Depressive Disorder, Major

Duloxetine hydrochloride

Phase 3

Diabetic Neuropathy, Painful

Tirzepatide Dose 1

Phase 3

Type2 Diabetes

Insulin Degludec

Phase 3

Type 2 Diabetes Mellitus

simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder

Phase 3

Diabetes Mellitus, Type 2

Duloxetine hydrochloride - 40 mg

Phase 3

Diabetic Neuropathies

Intramuscular Glucagon

Phase 3

Diabetes Mellitus, Type 1

Biguanides (BG)

Phase 3

Type 2 Diabetes Mellitus

Exenatide

Phase 3

Diabetes Mellitus, Type 2

Oral Antihyperglycemic Medications (OAMs)

Phase 3

Type 2 Diabetes Mellitus

Oral Olanzapine

Phase 3

Schizophrenic Disorders

lomustine

Phase 3

Glioblastoma

semagacestat

Phase 3

Alzheimer's Disease

Abiraterone

Phase 3

Prostatic Neoplasms

oxaliplatin

Phase 3

Colorectal Cancer

Insulin Lispro 6 Day (6D)

Phase 3

Diabetes Mellitus, Type 1

LY450139

Phase 3

Alzheimer's Disease

Remternetug

Phase 3

Alzheimer's Disease

Insulin lispro mix 25

Phase 3

Diabetes Mellitus Type 2

cDMARD

Phase 3

Rheumatoid Arthritis

Fluoxetine

Phase 3

Major Depressive Disorder

Orforglipron

Phase 3

Obesity

LY2963016

Phase 3

Type 1 Diabetes

pemetrexed

Phase 3

Non-Small Cell Lung Cancer

Ustekinumab

Phase 3

Plaque Psoriasis

Methylphenidate Hydrochloride

Phase 3

Attention Deficit Hyperactivity Disorder

gemcitabine hydrochloride

Phase 3

Breast Cancer

Adalimumab

Phase 3

Rheumatoid Arthritis

Vepugratinib

Phase 3

Carcinoma, Transitional Cell

Ruboxistaurin mesylate

Phase 3

Diabetic Neuropathies

Anastrozole

Phase 3

Breast Cancer

Erlotinib

Phase 3

Non Small Cell Lung Cancer

solanezumab

Phase 3

Alzheimer's Disease

Finasteride

Phase 3

Benign Prostatic Hyperplasia

Insulin Lispro Protamine Suspension (ILPS)

Phase 3

Diabetes Mellitus, Type 2

Glucagon Nasal Powder

Phase 3

Diabetes Mellitus

GEMZAR

Phase 3

Pancreatic Neoplasms

Lasmiditan 50 mg

Phase 3

Migraine With or Without Aura

Galcanezumab 300 mg

Phase 3

Chronic Cluster Headache

Standard Adjuvant Endocrine Therapy

Phase 3

Breast Cancer

Tadalafil 5 mg

Phase 3

Benign Prostatic Hyperplasia (BPH)

Human Insulin NPH

Phase 3

Diabetes Mellitus, Type 2

Drotrecogin alfa (activated)

Phase 3

Sepsis

Dulaglutide

Phase 3

Type 2 Diabetes Mellitus

Muvalaplin

Phase 3

Elevated Lp(a)

olanzapine pamoate depot

Phase 3

Schizophrenia

LY2062430

Phase 3

Alzheimer's Disease

Salmon Calcitonin

Phase 3

Osteoporosis

LY3537031

Phase 3

Alcohol Use Disorder

Vinorelbine

Phase 3

Lung Neoplasms

cetuximab

Phase 3

Colorectal Neoplasms

Duloxetine

Phase 3

Urinary Stress Incontinence

Abiraterone acetate

Phase 3

Prostate Cancer

80 mg Ixekizumab Dosing Regimens 1, 2, and 3

Phase 3

Psoriasis

etoposide

Phase 3

Non-small Cell Lung Cancer

insulin lispro injection [rDNA origin] Low Mix

Phase 3

Type 2 Diabetes Mellitus

Ramucirumab (IMC-1211B) DP

Phase 3

Gastric Cancer

Clopidogrel

Phase 3

Acute Coronary Syndrome

Prasugrel

Phase 3

Sickle Cell Anemia

Commercially-available Aspirin

Phase 3

Acute Coronary Syndrome

Lepodisiran Sodium

Phase 3

Atherosclerotic Cardiovascular Disease (ASCVD)

Fumaric Acid Esters

Phase 3

Plaque Psoriasis

Testosterone MD-Lotion

Phase 3

Hypogonadism

Raloxifene HCL

Phase 3

Osteoporosis, Postmenopausal

Risedronate

Phase 3

Osteoporosis

LY4064809

Phase 3

Breast Neoplasms

Eloralintide

Phase 3

Overweight

Selpercatinib

Phase 3

Non-Small Cell Lung Cancer

Pembrolizumab

Phase 3

Carcinoma, Non-Small-Cell Lung

ERA as specific PAH treatment

Phase 3

Hypertension, Pulmonary

tamoxifen

Phase 3

Metastatic Breast Cancer

Escitalopram

Phase 3

Major Depressive Disorder

Haloperidol

Phase 3

Schizophrenia

LY2605541

Phase 3

Type 1 Diabetes Mellitus

Semaglutide

Phase 3

Type 2 Diabetes

liposomal doxorubicin

Phase 3

Genital Neoplasms, Female

Duloxetine 60 mg

Phase 3

Fibromyalgia

LANTUS®

Phase 3

Diabetes Mellitus, Type 2

Topical corticosteroid

Phase 3

Atopic Dermatitis

Insulin Lispro (U100)

Phase 3

Type 2 Diabetes

Olomorasib

Phase 3

Carcinoma, Non-Small-Cell Lung

Insulin Levemir

Phase 3

Diabetes Mellitus, Type 1

Bamlanivimab

Phase 3

COVID-19

Mirikizumab IV

Phase 3

Ulcerative Colitis

Olaratumab

Phase 3

Metastatic Pancreatic Cancer

Intramuscular Olanzapine Depot

Phase 3

Schizophrenia

Insulin lispro 2 day reservoir in-use

Phase 3

Diabetes Mellitus, Type 1

Other standard therapy for ADHD

Phase 3

Attention Deficit Hyperactivity Disorder

Retatrutide

Phase 3

Obesity

Baricitinib

Phase 3

Systemic Juvenile Idiopathic Arthritis

Metformin

Phase 3

Type 2 Diabetes Mellitus

cisplatin

Phase 3

Non-Small Cell Lung Cancer

teriparatide 20 micrograms/day subcutaneous

Phase 3

Osteoporosis, Post-Menopausal

salmon calcitonin 100 IU/day subcutaneous

Phase 3

Osteoporosis, Post-Menopausal

Galcanezumab

Phase 3

Chronic Migraine

Nasal Glucagon (NG)

Phase 3

Drug-specific Antibodies

Standard therapy for INCS

Phase 3

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Ixekizumab

Phase 3

Psoriasis

Lantus

Phase 3

Diabetes Mellitus, Type 2

Tirzepatide

Phase 3

Overweight

BEC2 Vaccine

Phase 3

Carcinoma, Small Cell Lung

Neutral protamine hagedorn insulin

Phase 3

Diabetes Mellitus, Type 2

Lasmiditan 100 mg

Phase 3

Acute Migraine

Lebrikizumab

Phase 3

Atopic Dermatitis

Gefitinib

Phase 3

Non Small Cell Lung Cancer

LY3537982

Phase 3

Carcinoma, Non-Small-Cell Lung

80 mg ixekizumab Dosing Regimen

Phase 3

Psoriasis

amantadine

Phase 3

Schizophrenia

Insulin

Phase 3

Diabetes Mellitus, Type 2

Ethinyl estradiol

Phase 3

Turner Syndrome

Remternetug (IV)

Phase 3

Alzheimer's Disease

LY2216684

Phase 3

Major Depressive Disorder

dirucotide

Phase 3

Secondary Progressive Multiple Sclerosis

Insulin Aspart

Phase 3

Type 2 Diabetes Mellitus

Ramucirumab DP (IMC-1121B)

Phase 3

Hepatocellular Carcinoma

Injectable insulin

Phase 3

Diabetes Mellitus, Type 2

5 mg Tadalafil

Phase 3

Benign Prostate Hyperplasia

Dapagliflozin

Phase 3

Type 2 Diabetes

LY353381

Phase 3

Breast Neoplasms

Insulin Efsitora Alfa

Phase 3

Type 2 Diabetes

Insulin Peglispro

Phase 3

Type 2 Diabetes Mellitus

SSRI

Phase 3

Major Depressive Disorder

olanzapine

Phase 3

Bipolar Disorder I or II

leuprorelin

Phase 3

Idiopathic Short Stature (ISS)

venlafaxine

Phase 3

Anxiety Disorders

Pemetrexed - Before Protocol Amendment

Phase 2

Non Small Cell Lung Cancer

Erbitux (Cetuximab)

Phase 2

Colorectal Neoplasms

LY2140023

Phase 2

Schizophrenia

LY3209590

Phase 2

Type 2 Diabetes Mellitus

IMC-1121B (ramucirumab)

Phase 2

Carcinoma, Non-Small-Cell Lung

LY3016859

Phase 2

Osteoarthritis

MORF-057

Phase 2

Inflammatory Bowel Diseases

Prexasertib

Phase 2

Ovarian Cancer

LY2409021

Phase 2

Diabetes Mellitus, Type 2

LY3473329

Phase 2

Lipoprotein Disorder

LY517717

Phase 2

Total Knee Replacement

LY3857210

Phase 2

Diabetic Peripheral Neuropathic Pain

120 mg LY2784544

Phase 2

Neoplasms, Hematologic

Cixutumumab

Phase 2

Non-Small-Cell Lung Carcinoma

LY2189102

Phase 2

Arthritis, Rheumatoid

LY3451838

Phase 2

Migraine

Platinol

Phase 2

Carcinoma, Transitional Cell

Brenipatide

Phase 2

Asthma

LY2623091

Phase 2

Primary Hypertension

LY3938577

Phase 2

Diabetes Mellitus, Type 2

LY2428757

Phase 2

Diabetes Mellitus, Type 2

LOXO-292

Phase 2

Medullary Thyroid Cancer

olanzapine-RAIM

Phase 2

Schizophrenia

Tadalafil- Tablet or Oral suspension

Phase 2

Pulmonary Arterial Hypertension

LY3023414

Phase 2

Prostate Cancer Metastatic

LY3561774

Phase 2

Dyslipidemias

LY3848575

Phase 2

Neuropathic Pain

Mevidalen

Phase 2

Alzheimer Disease

ALIMTA

Phase 2

Colorectal Cancer

Bimagrumab

Phase 2

Obesity

LY2603618

Phase 2

Non Small Cell Lung Cancer

LY2439821

Phase 2

Rheumatoid Arthritis

Emibetuzumab

Phase 2

Carcinoma, Non-Small-Cell Lung

Testosterone Solution 2%

Phase 2

Ejaculatory Dysfunction

Cetuximab + platinum + gemcitabine

Phase 2

Non-Small-Cell Lung Carcinoma

irinotecan

Phase 2

Metastatic Colorectal Cancer

Cyclophosphamide

Phase 2

Desmoplastic Small Round Cell Tumor

Ramucirumab DP

Phase 2

Carcinoma of Urinary Tract

LY545694 49 mg

Phase 2

Osteoarthritis Knee Pain

LY2181308 sodium

Phase 2

Prostate Cancer

LY3819469

Phase 2

Lipoprotein Disorder

LY686017

Phase 2

Social Phobia

LY573636-sodium

Phase 2

Ovarian Cancer

Zagotenemab

Phase 2

Alzheimer Disease (AD)

STX-478

Phase 2

Breast Cancer

LY2452473

Phase 2

Erectile Dysfunction

Raloxifene

Phase 2

Vasomotor Symptoms

LY3305677

Phase 2

Obesity

LY450139 dihydrate

Phase 2

Alzheimer's Disease

LY2196044

Phase 2

Alcohol Dependence

LY3009104

Phase 2

Arthritis, Rheumatoid

IMC-A12 (Cixutumumab)

Phase 2

Adenocarcinoma of the Prostate

LY2090314

Phase 2

Leukemia

Eltrekibart

Phase 2

Hidradenitis Suppurativa

Temozolomide

Phase 2

Sarcoma, Ewing

Bortezomib

Phase 2

Multiple Myeloma

Sunitinib

Phase 2

Metastatic Renal Cell Carcinoma

Leucovorin (LV)

Phase 2

Colorectal Cancer

Pemetrexed Phase 1

Phase 2

Non-Small Cell Lung Cancer

LY3462817

Phase 2

Rheumatoid Arthritis

LY3015014

Phase 2

Hypercholesterolemia

LY2624803

Phase 2

Primary Insomnia

Mibavademab

Phase 2

Obesity

LY3972406

Phase 2

Plaque Psoriasis

Pemetrexed - Phase 1

Phase 2

Ovarian Cancer

Loperamide

Phase 2

Breast Cancer

5-Fluorouracil

Phase 2

Head and Neck Cancer

LY3841136

Phase 2

Obesity

Leucovorin

Phase 2

Stomach Cancer

LY3039478

Phase 2

T-cell Acute Lymphoblastic Leukemia

LY3437943

Phase 2

Obesity

LY2510924

Phase 2

Extensive Stage Small Cell Lung Carcinoma

LY293111

Phase 2

Pancreatic Cancer

LY2828360

Phase 2

Osteoarthritis, Knee

Prasugrel (CS-747)

Phase 2

Cardiovascular Diseases

sPLA2 Inhibitor

Phase 2

Sepsis

LY3526318

Phase 2

Chronic Low-back Pain

LY2495655

Phase 2

Pancreatic Cancer

IMC-1121B

Phase 2

Cancer

LY3202626

Phase 2

Alzheimer Disease

Pemetrexed 500 mg/m2

Phase 2

Non-small Cell Lung Cancer

IMC-18F1

Phase 2

Breast Cancer

PPAR alpha

Phase 2

Hypercholesterolemia

5 - FU

Phase 2

Solid Tumor

LY3154207

Phase 2

Lewy Body Dementia

arzoxifene hydrochloride

Phase 2

Endometrial Cancer

Triamcinolone (Optional)

Phase 2

Atopic Dermatitis

depot octreotide

Phase 2

Carcinoma

Subcutaneous Teriparatide

Phase 2

Osteoporosis

Folinic acid

Phase 2

Colorectal Carcinoma

LY3556050

Phase 2

Diabetic Peripheral Neuropathy

Dacarbazine

Phase 2

Metastatic Malignant Melanoma

LY3871801

Phase 2

Rheumatoid Arthritis

LY2157299

Phase 2

Hepatocellular Carcinoma

LY2181308

Phase 2

Non-small Cell Lung Cancer

tasisulam

Phase 2

Metastatic Melanoma

LY3502970

Phase 2

Obesity

LY2541546

Phase 2

Osteoporosis

S-1

Phase 2

Metastatic Gastric Adenocarcinoma

Atorvastatin

Phase 2

Dyslipidemias

LY2228820

Phase 2

Epithelial Ovarian Cancer

mitomycin C

Phase 2

Superficial Bladder Cancer

LY3295668

Phase 2

Neoplasms

LY2523355

Phase 2

Metastatic Breast Cancer

Enoxaparin

Phase 2

Submassive Pulmonary Embolism

Sivelestat

Phase 2

Respiratory Distress Syndrome, Adult

Icrucumab

Phase 2

Colon Cancer

Hydrochlorothiazide

Phase 2

Mild Hypertension

LY3041658

Phase 2

Hidradenitis Suppurativa

LY4100511

Phase 2

Plaque Psoriasis

LY2484595

Phase 2

Dyslipidemia

DC-806

Phase 2

Plaque Psoriasis

Granulocyte colony-stimulating factor (G-CSF)

Phase 2

Small Cell Lung Cancer

avastin

Phase 2

Colorectal Cancer

LY2951742

Phase 2

Migraine Headache

Enzyme-inducing antiepileptic drugs (EIAED)

Phase 2

Recurrent Glioblastoma

Mitoxantrone

Phase 2

Prostate Cancer

LY4065967

Phase 2

Diabetic Peripheral Neuropathic Pain

LY3457263

Phase 2

Type 2 Diabetes

Solbinsiran

Phase 2

Severe Hypertriglyceridemia

Dinutuximab

Phase 2

Relapsed Solid Tumor

LY451395

Phase 2

Alzheimer's Disease

LY3016859 ISA

Phase 2

Osteoarthritis, Knee

Ramucirumab (IMC-1121B)

Phase 2

Breast Cancer

LOXO-305

Phase 2

Leukemia, Lymphoid

Methotrexate

Phase 2

Arthritis, Rheumatoid

Enzastaurin 500 milligram (mg) Once Daily (QD)

Phase 2

Glioblastoma Multiforme

naveglitazar

Phase 2

Diabetes Mellitus, Non-Insulin-Dependent

Mazdutide

Phase 2

Alcohol Use Disorder

Macupatide

Phase 2

Obesity

LY2875358

Phase 2

Carcinoma, Non-Small-Cell Lung

Merestinib

Phase 2

Biliary Tract Cancer

Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)

Phase 2

Carcinoma, Non-Small-Cell Lung

LY3541860

Phase 2

Rheumatoid Arthritis

5 - Fluorouracil

Phase 2

Solid Tumor

Nab-Paclitaxel

Phase 2

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

prasugrel 10 mg

Phase 2

Coronary Arteriosclerosis

LY041001 (HIIP)

Phase 2

Diabetes Mellitus, Type 2

IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)

Phase 2

Hepatocellular Carcinoma

LY3372689

Phase 2

Alzheimer Disease

Tamsulosin

Phase 2

Benign Prostatic Hyperplasia

Folic Acid

Phase 2

Non Small Cell Lung Cancer

pegfilgrastim

Phase 2

Ovarian Cancer

Prophylactic Loperamide

Phase 2

Metastatic Breast Cancer

LY2189265 and Lifestyle Measures

Phase 2

Diabetes Mellitus, Type 2

Standard of Care Single Agent Chemotherapy

Phase 2

Hormone Receptor Positive Breast Cancer

Nasal Glucagon 1 mg

Phase 2

Hypoglycemia

LY3549492

Phase 2

Obesity

Eplerenone

Phase 2

Chronic Kidney Disease

LY2422347

Phase 2

Sleep Initiation and Maintenance Disorders

Enzastaurin HCL

Phase 2

Non-Small-Cell Lung Carcinoma

IMC-A12

Phase 2

Prostate Cancer

human insulin inhalation powder (HIIP)

Phase 2

Diabetes Mellitus, Type 1

Risperidone

Phase 2

Schizophrenia

IMC-11F8 (necitumumab)

Phase 2

Metastatic Colorectal Cancer

Pirtobrutinib

Phase 2

Lymphoma, Non-Hodgkin

cetuximab (Erbitux ®)

Phase 2

Head and Neck Cancer

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
LLY News